[ { "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2026", "title": "Kvartalsrapport Q2 2026", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/ae1f417bd344855d4ceb5689dc8cbb99a", "date": "2026-08-06", "period": "2026-q2", "form_type": "interim-report", "report_key": "2026:q2", "filename": "Immunovia_Delarsrapport_Q2_2026.pdf", "text_chars": 54040, "sha256": "dd64257dad51d8e061ea554c48d6f4705c367b942e47569c3f24b02b0c4de2dc", "url": "/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q2-2026", "absolute_url": "https://spela.port0.org/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q2-2026", "txt_url": "/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q2-2026/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q2-2026/fulltext.txt", "parts": [ { "number": 1, "url": "/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q2-2026/part-001.html", "chars": 54040 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026", "title": "Kvartalsrapport Q1 2026", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a9f26903c3283771aae8384f7671d2965", "date": "2026-05-07", "period": "2026-q1", "form_type": "interim-report", "report_key": "2026:q1", "filename": "Immunovia_Delarsrapport_Q1_2026.pdf", "text_chars": 51299, "sha256": "82e9edf4b17f2d80be0d79e78b699609f88a57293279f46a189ff73ed86cb4b4", "url": "/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q1-2026", "absolute_url": "https://spela.port0.org/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q1-2026", "txt_url": "/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt", "parts": [ { "number": 1, "url": "/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html", "chars": 51299 } ] }, { "doc_id": "nasdaq-nordic-arsredovisning-2025", "title": "Årsredovisning 2025", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a003a0716b3c489d57e20b93cb41e4694", "date": "2026-04-10", "period": "2025-annual", "form_type": "annual-report", "report_key": "2025:annual", "filename": "Immunovia_AB_publ_Arsredovisning_2025.pdf", "text_chars": 180734, "sha256": "5835d188655b3c9f74e66c3ca06c35c44edf4fe2635245fa7978fbb34fd49ac5", "url": "/company/immunovia/documents/nasdaq-nordic-arsredovisning-2025", "absolute_url": "https://spela.port0.org/company/immunovia/documents/nasdaq-nordic-arsredovisning-2025", "txt_url": "/company/immunovia/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/immunovia/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt", "parts": [ { "number": 1, "url": "/company/immunovia/documents/nasdaq-nordic-arsredovisning-2025/part-001.html", "chars": 179700 }, { "number": 2, "url": "/company/immunovia/documents/nasdaq-nordic-arsredovisning-2025/part-002.html", "chars": 1032 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025", "title": "Kvartalsrapport Q4 2025", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a9a34f3722386ab8c29d882a04d530924", "date": "2026-02-24", "period": "2025-q4", "form_type": "year-end-report", "report_key": "2025:q4", "filename": "Bokslutskommunike_2025.pdf", "text_chars": 52683, "sha256": "2c0698add5bcd649088d1f7d8281bcf564f857711ae658b11c6ef51fe29ac391", "url": "/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q4-2025", "absolute_url": "https://spela.port0.org/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q4-2025", "txt_url": "/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt", "parts": [ { "number": 1, "url": "/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html", "chars": 52683 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025", "title": "Kvartalsrapport Q3 2025", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a54474f94e81f22f8f79db9eea5345820", "date": "2025-11-26", "period": "2025-q3", "form_type": "interim-report", "report_key": "2025:q3", "filename": "Immunovia_Delarsrapport_Q3_2025.pdf", "text_chars": 56928, "sha256": "b271e34cd6d179a57b367446b5b96b4cc5b4112ae24b7946235b01bd68a801dd", "url": "/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q3-2025", "absolute_url": "https://spela.port0.org/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q3-2025", "txt_url": "/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt", "parts": [ { "number": 1, "url": "/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html", "chars": 56928 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025", "title": "Kvartalsrapport Q2 2025", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a34ac50a6b43e88fafab56acaa607b867", "date": "2025-08-28", "period": "2025-q2", "form_type": "interim-report", "report_key": "2025:q2", "filename": "Immunovia_Delarsrapport_Q2_2025.pdf", "text_chars": 52590, "sha256": "cdfeedad1fe434d611f256fabfc55b97bcec98532c0badfbc45ba8a722de0883", "url": "/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q2-2025", "absolute_url": "https://spela.port0.org/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q2-2025", "txt_url": "/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt", "parts": [ { "number": 1, "url": "/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html", "chars": 52590 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025", "title": "Kvartalsrapport Q1 2025", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a4c207209390b4129817aaef9aed0e724", "date": "2025-05-14", "period": "2025-q1", "form_type": "interim-report", "report_key": "2025:q1", "filename": "Immunovia_Delarsrapport_Q1_2025.pdf", "text_chars": 49052, "sha256": "0998c3898b3b41de80babf449ac83e5b37f5faa319bc1318556c743722283306", "url": "/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q1-2025", "absolute_url": "https://spela.port0.org/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q1-2025", "txt_url": "/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt", "parts": [ { "number": 1, "url": "/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html", "chars": 49052 } ] }, { "doc_id": "nasdaq-nordic-arsredovisning-2024", "title": "Årsredovisning 2024", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/ad8f82bcabe6b205567357ba5b348dd01", "date": "2025-04-02", "period": "2024-annual", "form_type": "annual-report", "report_key": "2024:annual", "filename": "04010960.pdf", "text_chars": 171458, "sha256": "a4515cc4b07797264935dbcff2789cfdf6bf2969bf78883aebc2bec5143746bd", "url": "/company/immunovia/documents/nasdaq-nordic-arsredovisning-2024", "absolute_url": "https://spela.port0.org/company/immunovia/documents/nasdaq-nordic-arsredovisning-2024", "txt_url": "/company/immunovia/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/immunovia/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt", "parts": [ { "number": 1, "url": "/company/immunovia/documents/nasdaq-nordic-arsredovisning-2024/part-001.html", "chars": 171458 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024", "title": "Kvartalsrapport Q4 2024", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/abe1f005fa7d4e8f7d69c5443ceb81adf", "date": "2025-02-25", "period": "2024-q4", "form_type": "year-end-report", "report_key": "2024:q4", "filename": "02241926.pdf", "text_chars": 52992, "sha256": "05a51c33048ff12a3e5f66bd75db3a908aaa5cb10acc4deee349495cf05e0f99", "url": "/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q4-2024", "absolute_url": "https://spela.port0.org/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q4-2024", "txt_url": "/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt", "parts": [ { "number": 1, "url": "/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html", "chars": 52992 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024", "title": "Kvartalsrapport Q3 2024", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/acd18c866d911da5e4edb17009d06304a", "date": "2024-11-27", "period": "2024-q3", "form_type": "interim-report", "report_key": "2024:q3", "filename": "11263202.pdf", "text_chars": 52618, "sha256": "3a806c9f778c8ff2f04b94fd3a6cadfaaae0eedeae12f90fae764ae9eacf0266", "url": "/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q3-2024", "absolute_url": "https://spela.port0.org/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q3-2024", "txt_url": "/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt", "parts": [ { "number": 1, "url": "/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html", "chars": 52618 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024", "title": "Kvartalsrapport Q2 2024", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/af0c0fc60f1be8e297da6c1197aa1fd20", "date": "2024-08-05", "period": "2024-q2", "form_type": "interim-report", "report_key": "2024:q2", "filename": "08041669.pdf", "text_chars": 51580, "sha256": "df5a5c22c0fd818bab44b1bf857e17f3598c490f53539889486bf2758bb0e91a", "url": "/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q2-2024", "absolute_url": "https://spela.port0.org/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q2-2024", "txt_url": "/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt", "parts": [ { "number": 1, "url": "/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html", "chars": 51580 } ] }, { "doc_id": "nasdaq-nordic-arsredovisning-2023", "title": "Årsredovisning 2023", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a70dcaddefd57dbbd8b33a06aa4bc8ce2", "date": "2024-04-29", "period": "2023-annual", "form_type": "annual-report", "report_key": "2023:annual", "filename": "04299763.pdf", "text_chars": 190758, "sha256": "d777c5ae5528db58596f43a25d96705db22e4de68e60408f17d23268cefb6319", "url": "/company/immunovia/documents/nasdaq-nordic-arsredovisning-2023", "absolute_url": "https://spela.port0.org/company/immunovia/documents/nasdaq-nordic-arsredovisning-2023", "txt_url": "/company/immunovia/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/immunovia/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt", "parts": [ { "number": 1, "url": "/company/immunovia/documents/nasdaq-nordic-arsredovisning-2023/part-001.html", "chars": 178828 }, { "number": 2, "url": "/company/immunovia/documents/nasdaq-nordic-arsredovisning-2023/part-002.html", "chars": 11928 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2024", "title": "Kvartalsrapport Q1 2024", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a4e47857722f4af0dda08663c0e7fa1a0", "date": "2024-04-29", "period": "2024-q1", "form_type": "interim-report", "report_key": "2024:q1", "filename": "04289478.pdf", "text_chars": 47070, "sha256": "5d01116aeaa35137c5bc6e02fba92f7dc66eaaf2032bf2cd528e3d0173bc83f4", "url": "/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q1-2024", "absolute_url": "https://spela.port0.org/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q1-2024", "txt_url": "/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt", "parts": [ { "number": 1, "url": "/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q1-2024/part-001.html", "chars": 47070 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2023", "title": "Kvartalsrapport Q4 2023", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a6a47d32a9fd60e7b8bd200d032a951f0", "date": "2024-02-21", "period": "2023-q4", "form_type": "year-end-report", "report_key": "2023:q4", "filename": "02202332.pdf", "text_chars": 57447, "sha256": "20dcbea82e241e3a7bedc430d19d1720115f11eee5508a11099b01cb5c79b86f", "url": "/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q4-2023", "absolute_url": "https://spela.port0.org/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q4-2023", "txt_url": "/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt", "parts": [ { "number": 1, "url": "/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q4-2023/part-001.html", "chars": 57447 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2023", "title": "Kvartalsrapport Q3 2023", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/aec57324595315300aeeaee2a72ce03c8", "date": "2023-11-09", "period": "2023-q3", "form_type": "interim-report", "report_key": "2023:q3", "filename": "11081246.pdf", "text_chars": 56339, "sha256": "5081fce965b0350cac4df4eaad2f897e4684914745bee61c519ec6e2a962c46d", "url": "/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q3-2023", "absolute_url": "https://spela.port0.org/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q3-2023", "txt_url": "/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt", "parts": [ { "number": 1, "url": "/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q3-2023/part-001.html", "chars": 56339 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2023", "title": "Kvartalsrapport Q2 2023", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/aef1296542205e39180d2c63a5aa2de4b", "date": "2023-08-30", "period": "2023-q2", "form_type": "interim-report", "report_key": "2023:q2", "filename": "08294671.pdf", "text_chars": 55030, "sha256": "d3df7868ec951e4987f7a56ad78374700ecc020c9947dc06d022301d0b5ac249", "url": "/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q2-2023", "absolute_url": "https://spela.port0.org/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q2-2023", "txt_url": "/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt", "parts": [ { "number": 1, "url": "/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q2-2023/part-001.html", "chars": 55030 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2023", "title": "Kvartalsrapport Q1 2023", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a624425c262bab7d0258e72e8ab48e1f2", "date": "2023-05-23", "period": "2023-q1", "form_type": "interim-report", "report_key": "2023:q1", "filename": "05220986.pdf", "text_chars": 50387, "sha256": "dcf8f047fbd1ff2984ea9e64777cc635cc14a2016082b71926900a213fd51942", "url": "/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q1-2023", "absolute_url": "https://spela.port0.org/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q1-2023", "txt_url": "/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt", "parts": [ { "number": 1, "url": "/company/immunovia/documents/nasdaq-nordic-kvartalsrapport-q1-2023/part-001.html", "chars": 50387 } ] }, { "doc_id": "mfn-mfn-bolagssida-och-bolagsmetadata", "title": "MFN bolagssida och bolagsmetadata", "source": "MFN", "source_class": "mfn", "source_url": "https://mfn.se/all/a/immunovia", "date": null, "period": null, "form_type": "company-page", "report_key": null, "filename": "company.txt", "text_chars": 12747, "sha256": "67e0bf9104a6b557da1224ace8b76651511ee1dbc424757b27b7911e0bcb4e57", "url": "/company/immunovia/documents/mfn-mfn-bolagssida-och-bolagsmetadata", "absolute_url": "https://spela.port0.org/company/immunovia/documents/mfn-mfn-bolagssida-och-bolagsmetadata", "txt_url": "/company/immunovia/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/immunovia/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt", "parts": [ { "number": 1, "url": "/company/immunovia/documents/mfn-mfn-bolagssida-och-bolagsmetadata/part-001.html", "chars": 12747 } ] } ]